Full Press Release Details
Corp. Announces Plans to Be Among International First Movers
Pending Completion of Landmark Change in US Drug Policy
United Kingdom--(Newsfile Corp. - May 10, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"),
an international medical cannabis company, today announces it is actively following the landmark change in federal US policy to reschedule
cannabis under the Controlled Substances Act ("CSA"). It has been widely reported that as of April 30, 2024 the DEA plans to
reclassify cannabis as a Schedule III substance. The Company believes this imminent rescheduling may reinvigorate capital markets and
could lead to changes in NASDAQ and NYSE rules on listing plant-touching U.S. companies. Should this occur and provided NASDAQ rule changes,
Akanda has strategic plans to become a leader in consolidating US-based operators.
U.S. Department of Health and Human Services ("HHS") report was made public on January 29, 2024. The August 2023 report submitted
to the Drug Enforcement Agency (DEA), recommended that cannabis be rescheduled as a Schedule III controlled substance. The DEA's subsequent
proposal, which still must be reviewed by the White House Office of Management and Budget, would recognize the medical uses of cannabis
and acknowledge it has less potential for abuse than some of the nation's most dangerous drugs. Once
OMB signs off, the DEA will take public comment on the plan to move marijuana from its current classification as a Schedule I drug and
-after the public-comment period -the agency would publish the final rule.
decision marks both a symbolic and a very tangible victory. Once enacted, we believe this move should provide immediate benefits to both
the state-legal industry and cannabis consumers - such as providing lower prices for retail products and providing greater flexibility
to who can legally consume cannabis and where. Ideally, it will also encourage lawmakers at the state and federal level to take further
steps to amend and repeal cannabis criminalization.
Field commented, "Akanda's Board and Management have subject matter expertise in multiple global markets including the United
States. We are closely monitoring the loosening of federal regulations and plan to explore US opportunities. Some US markets are more
depressed than others offering a unique opportunity to capitalize on low entry prices of licenses or licensed operations."
is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to
high quality and affordable products. Akanda's portfolio includes CanMart, a UK-based fully licensed pharmaceutical importer and distributor
which supplies pharmacies and clinics within the UK. The Company's seed-to-patient supply chain also includes partnerships Cellen Life
Sciences' Leva Clinic, one of the first fully digital pain clinics in the UK. Akanda also acquired
the right to develop a Canadian farming property in British Columbia, including farming land and related operations and licenses. The
Company plans to develop THC and cannabinoid (CBD) facilities at this site.
with Akanda: Email | Website | LinkedIn | Twitter | Instagram
Note Regarding Forward-Looking Information and Statements
press release contains certain "forward-looking information" within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative
of historical facts or information or current condition, but instead represent only Akanda's beliefs regarding future events, plans or
objectives, many of which, by their nature, are inherently uncertain and outside of Akanda's control. Generally, such forward-looking
information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates" or "does not anticipate", or "believes", or variations of such words
and phrases or may contain statements that certain actions, events or results "may", "could", "would",
"might" or "will be taken", "will continue", "will occur" or "will be achieved" and
similar expressions and include statements regarding the timing and completion of the proposed offering. Forward-looking information
may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth
plans. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this
press release, and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained
or referenced herein, except in accordance with applicable securities laws.